EU antitrust regulators again extend their decision deadline on the Google/Fitbit merger, now Jan. 8, 2021; meanwhile Fitbit keeps hemorrhaging market share
Context & Ripple Effects
The EU's review of Google's $2.1B Fitbit bid has moved from screening to scrutiny: the Commission opened an in-depth investigation in August over the data the deal would hand Google, and by late September sources said an approval was being lined up. Today's extension to Jan. 8 stretches the clock past the original August 4 preliminary-review endpoint, with Fitbit's market share eroding while the deal sits in limbo.
The stakes are data, not devices: the July examination centered on whether Fitbit's health data could entrench Google's search and advertising businesses. The delay signals the Commission is still shaping the conditions under which that data changes hands.
First-order effects
- Fitbit keeps ceding wearables market share during the extended review — every week of limbo weakens the asset Google is buying and narrows Fitbit's standalone options.
- Google's integration planning stays frozen: no data migration or product roadmap work can begin until the Commission rules on Jan. 8.
Second-order effects
- With sources pointing to approval, the real negotiation is over commitments — privacy and user-consent remedies that would become the template for how the EU prices data-heavy acquisitions.
- Rival wearable makers gain a window to court Fitbit's defectors, converting the regulatory delay into share gains of their own.
Third-order effects
- If the pattern holds, EU merger clearance for data acquisitions comes bundled with behavioral commitments rather than blocks — a precedent the Commission's eventual conditional approval confirmed, and whose long tail surfaced in 2024 when Google removed third-party apps and watch faces from EU Fitbit watches citing regulatory requirements.
- Wearables consolidation around platform owners accelerates: independent device makers face a choice between shrinking alone or selling their data exhaust to an ad-funded acquirer.
The trend: EU merger review is becoming the de facto pricing mechanism for data acquisitions, with privacy commitments — not deal blocks — defining what platform owners may do with acquired health data.